Skip to main content
Healthcare

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

Feed excerpt — reported by STAT News

Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.